AzTrials
AzTrials

Liver TransplantationNCT05822570

Oxygen Dissociation Curve in Patients Undergoing Orthotopic Liver Transplantation

An observational study of Liver Transplantation, run by Medical University Innsbruck at 1 site in Austria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hemoglobin (Hb) is the molecule responsible for the transport of oxygen (O2) to the tissues in mammals. The p50 and the Hill coefficient (HC) best describe the ODC. The interaction between Hb and O2 can be influenced by many agents and conditions like temperature, pH, pCO2 and 2,3-diphosphoglycerate (2,3-DPG). Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Liver Transplantation
What is being tested?
Assessment of Oxygen Dissociation Curve (ODC)
How many people
30 participants
Where
1 siteAustria
Study dates
1 May 2023to 31 Oct 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • Adult, Older adult

Study population: Patients scheduled for orthotopic liver transplantation

Who may be able to join

  • Patien scheduled for LTX
  • Age 18 years to 99 years
  • Signed informed content form.

Who cannot join

  • Known hemoglobinopathy
  • Need for more than 3 packed erythrocytes before assessment at T4.
  • preoperative predicted need for more than 3 based on study team
  • MELD score < 10
  • stay at high attitude (>3000 m) for more days over the last 4 weeks

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Medical University Innsbruck

    Innsbruck, Tyrol, 6020

Other trials in Austria

About this study

Hemoglobin (Hb) is the molecule responsible for the transport of oxygen (O2) to the tissues in mammals.

The p50 and the Hill coefficient (HC) best describe the ODC. The interaction between Hb and O2 can be influenced by many agents and conditions like temperature, pH, pCO2 and 2,3-diphosphoglycerate (2,3-DPG).

Read more

During liver transplantation numerous profound physiological changes occur, linked to the different stages of the surgical procedure.

Previous studies in humans and animals undergoing liver transplantation have shown that while the ODC seems preserved during preparation and the anhepatic phase, a left shift of the ODC occurs after reperfusion . This left shift of the ODC could imply a decreased release of oxygen to the tissues, probably worsening hemodynamic instability.

With this pilot study the investigator aim to measure ODCs at baseline and at different stages during orthotopic liver transplantation in patients in order to get deeper understanding of oxygen delivery and supply during liver transplantation surgery.

Read the detailed description

Hemoglobin (Hb) is the molecule responsible for the transport of oxygen (O2) to the tissues in mammals.

First described by Bohr at the beginning of the 20th century, the interaction between oxygen and hemoglobin is represented by the oxygen-hemoglobin dissociation curve (ODC), which has a sigmoid shape. The p50 and the Hill coefficient (HC) best describe the ODC. The p50 represents the partial pressure of O2 at which the 50% of Hb is saturated with O2, and the Hill coefficient represents the maximal steepness of the curve in the logarithmic Hill plot. The interaction between Hb and O2 can be influenced by many agents and conditions like temperature, pH, pCO2 and 2,3-diphospoglycerate (2,3-DPG)(1). An increase in p50 indicates a shift of the ODC to the right and a decrease in Hb-O2 affinity, whereas a decrease of the p50 indicates a shift of the ODC to the left and an increased affinity .

Liver disease, in particular liver cirrhosis, is thought to influence the ODC in many ways, a right shift due to a stimulation in the production of 2,3-DPG has been described. Also Caldwell et al. showed a right shift of the ODC for cirrhotic patients, although they couldn't demonstrate the reason for this shift and only postulated that the acid-base balance in the red blood cell or the cation concentration could be abnormal in these patients. Patients with End Stage Liver Disease (ESLD) show an hyperdynamic circulation, an adaptive reaction to a possible occult ischemia and splanchnic vasodilatation (8). Under physiological conditions, the oxygen consumption (VO2) is independent of oxygen delivery (DO2). When DO2 decreases under a critical level, oxygen extraction from hemoglobin can increase to maintain VO2. Under this critical DO2 level, as oxygen extraction has reached its maximum, VO2 will decrease, this state is called physiological oxygen supply dependency. It has been postulated that in some diseases and conditions, such as ARDS, sepsis, acute liver failure or extensive surgery, a pathological oxygen supply dependency may exist. When considering the whole oxygen supply, it has to be taken into account that measurements of DO2 and VO2 alone don't acknowledge the impact of the ODC on the effective delivery of oxygen in the tissue. Also under normal conditions where DO2 and VO2 are in the normal range, the oxygen extraction rate could be impaired by changes in the ODC. Orthotopic liver transplantation (OLT) is an important step in the therapy of end stage liver disease and represent a complex intervention, both from the surgical and anesthesiologic point of view. During liver transplantation numerous profound physiological changes occur, linked to the different stages of the surgical procedure. At first, in the preparation phase, the native liver and the vessels are dissected and bleeding may occur. In the second phase of OLT the inferior vena cava will be clamped, with resulting hemodynamic instability from reduced preload and congestion in the inferior part of the body. During this so called anhepatic phase lactate and other metabolisms end products accumulate. After anastomosis of the vena cava and the portal vein, the reperfusion phase begins. Here, due to the return in the circulation of acidotic blood and accumulated metabolites from the inferior part of the body, profound hemodynamic instability with decreased blood pressure can be observed. Previous studies in humans and animals undergoing liver transplantation have shown that while the ODC seems preserved during preparation and the anhepatic phase, a left shift of the ODC occurs after reperfusion . This left shift of the ODC could imply a decreased release of oxygen to the tissues, probably worsening hemodynamic instability.

With this pilot study the investigator aim to measure ODCs at baseline and at different stages during orthotopic liver transplantation in patients in order to get deeper understanding of oxygen delivery and supply during liver transplantation surgery.

Being tested
Assessment of Oxygen Dissociation Curve (ODC)
Keywords
Liver Transplantation, Oxygen dissociation curve

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Assessment of Oxygen Dissociation Curve (ODC)Diagnostic test

    ODC will be assessed at 5 timepoints: T0 after installation of arterial catheter, T1 before clamping of the liver, T2 5-10 min before reperfusion of the liver graft, T3 45 min after reperfusion, T4 1 h after T3 or at end of surgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oxygen Dissocation Curve

    Oxgen delivery curve characteristics based on p50 values, Hill-coefficient and 2,3 DPG

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2023
  2. Study start1 May 2023
  3. Primary completion30 Sep 2024
  4. Study completion31 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05822570
Sponsor's protocol ID
O2DO2 in LTX
Status last verified
Nov 2024
First submitted
6 Apr 2023
Last updated
26 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Transplantation, run by Medical University Innsbruck at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oxygen Dissocation Curve (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in